One fifth of hospitalizations for peptic ulcer-related bleeding are potentially preventable

World J Gastroenterol. 2014 Aug 14;20(30):10504-11. doi: 10.3748/wjg.v20.i30.10504.

Abstract

Aim: To calculate the proportion of potentially preventable hospitalizations due to peptic ulcer disease (PUD), erosive gastritis (EG) or duodenitis (ED).

Methods: Retrospective cohort study using ICD-10 codes to identify all patients with upper gastrointestinal hemorrhage secondary to endoscopically proven PUD, EG or ED during the period from March 2007 to October 2010 in three major metropolitan hospitals in Melbourne, Australia. Patients were divided into "high risk" (those who would benefit from gastroprotection) and "not high risk" groups as defined by established guidelines. Mean Rockall score, transfusion requirement, length of stay, rebleeding rates, need for surgery and in-hospital mortality was compared between "high risk" and "not high risk" groups. Within the "high risk" group, those on gastroprotection and those with no gastroprotection were also compared.

Results: Five hundred and seven patients were included for analysis of which 174 were classified as high risk. Median values of complete Rockall Score (5 vs 4, P = 0.002) and length of stay (5 d vs 4 d, P = 0.04) were higher in the high risk group but in-hospital mortality was lower (0.6% vs 3.9%, P = 0.03). 130 out of the 174 patients in the high risk group were not taking recommended gastroprotective therapy prior to hospitalization. Past history of PUD (OR = 3.7, P = 0.006) and clopidogrel use (OR = 3.2, P = 0.007) significantly predicted prescription of gastroprotective therapy. Using proton pump inhibitor protection rates of 50%-85% from published studies, an estimation of 13% to 22% of the total number of the hospitalizations due to PUD or EG/ED related bleeding may have been preventable.

Conclusion: Up to one fifth of all hospitalizations for bleeding secondary to PUD or EG/ED are potentially preventable.

Keywords: Gastrointestinal hemorrhage; Gastroprotection; Non-steroidal anti-inflammatory drug; Peptic ulcer; Prevention; Proton pump inhibitor.

Publication types

  • Multicenter Study

MeSH terms

  • Chi-Square Distribution
  • Duodenitis / complications
  • Duodenitis / diagnosis
  • Duodenitis / drug therapy*
  • Duodenitis / mortality
  • Endoscopy, Gastrointestinal
  • Female
  • Gastritis / complications
  • Gastritis / diagnosis
  • Gastritis / drug therapy*
  • Gastritis / mortality
  • Gastrointestinal Hemorrhage / diagnosis
  • Gastrointestinal Hemorrhage / etiology
  • Gastrointestinal Hemorrhage / mortality
  • Gastrointestinal Hemorrhage / prevention & control*
  • Hospital Mortality
  • Hospitalization*
  • Humans
  • Length of Stay
  • Logistic Models
  • Male
  • Middle Aged
  • Odds Ratio
  • Peptic Ulcer Hemorrhage / diagnosis
  • Peptic Ulcer Hemorrhage / mortality
  • Peptic Ulcer Hemorrhage / prevention & control*
  • Predictive Value of Tests
  • Proton Pump Inhibitors / therapeutic use*
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Time Factors
  • Victoria

Substances

  • Proton Pump Inhibitors